A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma (CARTITUDE-2)
Enrolling By Invitation
18-99 years
All
Phase
N/A
40 participants needed
1 Location
Brief description of study
The purpose of this study is to see if JNJ-68284528 is safe and useful for treating patients with relapsed or refractory multiple myeloma.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Multiple Myeloma
-
Age: Between 18 Years - 99 Years
-
Gender: All
Male or Female. Age 18 or older, diagnosed multiple myeloma
Updated on
09 Mar 2024.
Study ID: 834074
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
